



Universiteit  
Leiden  
The Netherlands

## Measuring symptoms and functioning in glioma patients

Peeters, M.C.M.

### Citation

Peeters, M. C. M. (2022, December 7). *Measuring symptoms and functioning in glioma patients*. Retrieved from <https://hdl.handle.net/1887/3494291>

Version: Publisher's Version

[Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

License: <https://hdl.handle.net/1887/3494291>

**Note:** To cite this publication please use the final published version (if applicable).

## Referenties

1. Pace A, Dirven L, Koekkoek JAF, Golla H, Fleming J, Rudà R, et al. European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. *The Lancet Oncology*. 2017;18(6):e330-e40.
2. Kerrigan S, Erridge S, Liaquat I, Graham C, Grant R. Mental incapacity in patients undergoing neuro-oncologic treatment: a cross-sectional study. *Neurology*. 2014;83(6):537-41.
3. Sizoo EM, Pasman HR, Buttolo J, Heimans JJ, Klein M, Deliens L, et al. Decision-making in the end-of-life phase of high-grade glioma patients. *European journal of cancer (Oxford, England : 1990)*. 2012;48(2):226-32.
4. Triebel KL, Martin RC, Nabors LB, Marson DC. Medical decision-making capacity in patients with malignant glioma. *Neurology*. 2009;73(24):2086-92.
5. Fritz L, Dirven L, Reijneveld JC, Koekkoek JA, Stiggelbout AM, Pasman HR, et al. Advance Care Planning in Glioblastoma Patients. *Cancers (Basel)*. 2016;8(11).
6. Peeters MC, Dirven L, Koekkoek JA, Numans ME, Taphoorn MJ. Prediagnostic presentations of glioma in primary care: a case-control study. *CNS oncology*. 2019;8(3):Cns44.
7. Peeters MCM, Dirven L, Koekkoek JAF, Gortmaker EG, Fritz L, Vos MJ, et al. Prediagnostic symptoms and signs of adult glioma: the patients' view. *Journal of neuro-oncology*. 2020;146(2):293-301.
8. Hamilton W, Kernick D. Clinical features of primary brain tumours: a case-control study using electronic primary care records. *BrJGenPract*. 2007;57(542):695-9.
9. Ozawa M, Brennan PM, Zienius K, Kurian KM, Hollingworth W, Weller D, et al. Symptoms in primary care with time to diagnosis of brain tumours. *Family practice*. 2018;35(5):551-8.
10. Schmidt-Hansen M, Berendse S, Hamilton W. Symptomatic diagnosis of cancer of the brain and central nervous system in primary care: a systematic review. *Family practice*. 2015;32(6):618-23.
11. Simpson GC, Forbes K, Teasdale E, Tyagi A, Santosh C. Impact of GP direct-access computerised tomography for the investigation of chronic daily headache. *The British journal of general practice : the journal of the Royal College of General Practitioners*. 2010;60(581):897-901.
12. Chittiboina P, Connor DE, Jr., Caldito G, Quillin JW, Wilson JD, Nanda A. Occult tumors presenting with negative imaging: analysis of the literature. *Journal of neurosurgery*. 2012;116(6):1195-203.
13. Hakan T, Çelikoglu E. Glioblastoma Shortly after a Normal Conventional Brain Magnetic Resonance Imaging: A Report of Two Cases and Review of the Literature. *Asian J Neurosurg*. 2021;16(2):433-6.
14. Kawauchi D, Ohno M, Honda-Kitahara M, Miyakita Y, Takahashi M, Yanagisawa S, et al. The clinical characteristics and outcomes of incidentally discovered glioblastoma. *Journal of neuro-oncology*. 2022.
15. Walter FM, Penfold C, Joannides A, Saji S, Johnson M, Watts C, et al. Missed opportunities for diagnosing brain tumours in primary care: a qualitative study of patient experiences. *The British journal of general practice : the journal of the Royal College of General Practitioners*. 2019;69(681):e224-e35.
16. Patiëntenfederatie Nederland [Available from: <https://begineengoedgesprek.nl/>].
17. Baum JM, Troxel A, Epperson CN, Cohen RB, Schmitz K, Stricker C, et al. Scan-associated distress in lung cancer: Quantifying the impact of "scanxiety". *Lung cancer (Amsterdam, Netherlands)*. 2016;100:110-3.
18. Peeters MCM, Zwinkels H, Koekkoek JAF, Vos MJ, Dirven L, Taphoorn MJB. The Impact of the Timing of Health-Related Quality of Life Assessments on the Actual Results in Glioma Patients: A Randomized Prospective Study. *Cancers (Basel)*. 2020;12(8).
19. Giesinger JM, Loth FLC, Aaronson NK, Arraras JI, Caocci G, Efficace F, et al. Thresholds for clinical impor-

- tance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. *Journal of clinical epidemiology*. 2020;118:1-8.
20. Ediebah DE, Coens C, Maringwa JT, Quinten C, Zikos E, Ringash J, et al. Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patients. *Annals of oncology : official journal of the European Society for Medical Oncology*. 2013;24(1):231-7.
  21. Peeters M, Ottenheijm G, Bienfait P, Eekers D, Gijtenbeek A, Hanse M, et al. Glioma patient-reported outcomes: patients and clinicians. *BMJ Support Palliat Care*. 2021.
  22. Kotronoulas G, Kearney N, Maguire R, Harrow A, Di Domenico D, Croy S, et al. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2014;32(14):1480-501.
  23. Brown RF, Butow PN, Dunn SM, Tattersall MH. Promoting patient participation and shortening cancer consultations: a randomised trial. *British journal of cancer*. 2001;85(9):1273-9.
  24. Detmar SB, Muller MJ, Schornagel JH, Wever LD, Aaronson NK. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. *Jama*. 2002;288(23):3027-34.
  25. Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2004;22(4):714-24.
  26. IJzerman-Korevaar M, Snijders TJ, de Graeff A, Teunissen S, de Vos FYF. Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review. *Journal of neuro-oncology*. 2018;140(3):485-96.
  27. Alonso J, Bartlett SJ, Rose M, Aaronson NK, Chaplin JE, Efficace F, et al. The case for an international patient-reported outcomes measurement information system (PROMIS®) initiative. *Health and quality of life outcomes*. 2013;11:210.
  28. Petersen MA, Aaronson NK, Arraras JL, Chie WC, Conroy T, Costantini A, et al. The EORTC CAT Core-The computer adaptive version of the EORTC QLQ-C30 questionnaire. *European journal of cancer (Oxford, England : 1990)*. 2018;100:8-16.
  29. Armstrong TS, Dirven L, Arons D, Bates A, Chang SM, Coens C, et al. Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report. *The Lancet Oncology*. 2020;21(2):e97-e103.
  30. Zerillo JA, Schouwenburg MG, van Bommel ACM, Stowell C, Lippa J, Bauer D, et al. An International Collaborative Standardizing a Comprehensive Patient-Centered Outcomes Measurement Set for Colorectal Cancer. *JAMA oncology*. 2017;3(5):686-94.
  31. Ong WL, Schouwenburg MG, van Bommel ACM, Stowell C, Allison KH, Benn KE, et al. A Standard Set of Value-Based Patient-Centered Outcomes for Breast Cancer: The International Consortium for Health Outcomes Measurement (ICHOM) Initiative. *JAMA oncology*. 2017;3(5):677-85.
  32. Morgans AK, van Bommel AC, Stowell C, Abraham JL, Basch E, Bekelman JE, et al. Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach. *Eur Urol*. 2015;68(5):891-8.
  33. Coomans MB, Peeters MCM, Koekkoek JAF, Schoones JW, Reijneveld J, Taphoorn MJB, et al. Research Objectives, Statistical Analyses and Interpretation of Health-Related Quality of Life Data in Glioma Research: A Systematic Review. *Cancers (Basel)*. 2020;12(12).
  34. Coomans MB, Taphoorn MJB, Aaronson NK, Baumert BG, van den Bent M, Bottomley A, et al. Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients. *Neurooncol Pract*. 2020;7(6):668-75.

## Appendices

35. Coens C, Pe M, Dueck AC, Sloan J, Basch E, Calvert M, et al. International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. *The Lancet Oncology.* 2020;21(2):e83-e96.
36. Brundage M, Blazebey J, Revicki D, Bass B, de Vet H, Duffy H, et al. Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. *Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation.* 2013;22(6):1161-75.
37. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandebroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet.* 2007;370(9596):1453-7.
38. Minaya Flores P, Berbis J, Chinot O, Auquier P. Assessing the quality of life among caregivers of patients with gliomas. *Neurooncol Pract.* 2014;1(4):191-7.
39. Faithfull S, Cook K, Lucas C. Palliative care of patients with a primary malignant brain tumour: case review of service use and support provided. *Palliat Med.* 2005;19(7):545-50.
40. Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, et al. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. *Jama.* 2017;318(2):197-8.
41. Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, et al. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* 2016;34(6):557-65.
42. Velikova G, Keding A, Harley C, Cocks K, Booth L, Smith AB, et al. Patients report improvements in continuity of care when quality of life assessments are used routinely in oncology practice: secondary outcomes of a randomised controlled trial. *European journal of cancer (Oxford, England : 1990).* 2010;46(13):2381-8.
43. Sztankay M, Wintner LM, Roggendorf S, Nordhausen T, Dirven L, Taphoorn MJB, et al. Developing an e-learning course on the use of PRO measures in oncological practice: health care professionals' preferences for learning content and methods. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.* 2021.
44. Hughes EF, Wu AW, Carducci MA, Snyder CF. What can I do? Recommendations for responding to issues identified by patient-reported outcomes assessments used in clinical practice. *J Support Oncol.* 2012;10(4):143-8.
45. Blackford AL, Wu AW, Snyder C. Interpreting and Acting on PRO Results in Clinical Practice: Lessons Learned From the PatientViewpoint System and Beyond. *Medical care.* 2019;57 Suppl 5 Suppl 1(Suppl 5 1):S46-s51.
46. Andreassen P, Neergaard MA, Brogaard T, Skorstengaard MH, Jensen AB. The diverse impact of advance care planning: a long-term follow-up study on patients' and relatives' experiences. *BMJ Support Palliat Care.* 2017;7(3):335-40.
47. Fritz L, Zwinkels H, Koekkoek JAF, Reijneveld JC, Vos MJ, Dirven L, et al. Advance care planning in glioblastoma patients: development of a disease-specific ACP program. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.* 2020;28(3):1315-24.
48. Nolte S, Liegl G, Petersen MA, Aaronson NK, Costantini A, Fayers PM, et al. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the United States. *European journal of cancer (Oxford, England : 1990).* 2019;107:153-63.
49. Korfage IJ, Carreras G, Arnfeldt Christensen CM, Billekens P, Bramley L, Briggs L, et al. Advance care planning in patients with advanced cancer: A 6-country, cluster-randomised clinical trial. *PLoS Med.* 2020;17(11):e1003422.

50. Jain A, Corriveau S, Quinn K, Gardhouse A, Vegas DB, You JJ. Video decision aids to assist with advance care planning: a systematic review and meta-analysis. *BMJ Open*. 2015;5(6):e007491.
51. Detering KM, Hancock AD, Reade MC, Silvester W. The impact of advance care planning on end of life care in elderly patients: randomised controlled trial. *Bmj*. 2010;340:c1345.
52. Finlay E, Shreve S, Casarett D. Nationwide veterans affairs quality measure for cancer: the family assessment of treatment at end of life. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2008;26(23):3838-44.
53. Walbert T. Integration of palliative care into the neuro-oncology practice: patterns in the United States. *Neurooncol Pract*. 2014;1(1):3-7.
54. Flechl B, Ackerl M, Sax C, Oberndorfer S, Calabek B, Sizoo E, et al. The caregivers' perspective on the end-of-life phase of glioblastoma patients. *Journal of neuro-oncology*. 2013;112(3):403-11.
55. Sizoo EM, Taphoorn MJ, Uitdehaag B, Heimans JJ, Deliens L, Reijneveld JC, et al. The end-of-life phase of high-grade glioma patients: dying with dignity? *The oncologist*. 2013;18(2):198-203.
56. Perkins HS, Geppert CMA, Gonzales A, Cortez JD, Hazuda HP. Cross-cultural similarities and differences in attitudes about advance care planning. *Journal of General Internal Medicine*. 2002;17(1):48-57.
57. Pereira-Salgado A, Mader P, Boyd LM. Advance care planning, culture and religion: an environmental scan of Australian-based online resources. *Australian Health Review*. 2018;42(2):152-63.
58. Jimenez G, Tan WS, Virk AK, Low CK, Car J, Ho AHY. Overview of Systematic Reviews of Advance Care Planning: Summary of Evidence and Global Lessons. *Journal of pain and symptom management*. 2018;56(3):436-59.e25.
59. Barnes K, Jones L, Tookman A, King M. Acceptability of an advance care planning interview schedule: a focus group study. *Palliat Med*. 2007;21(1):23-8.
60. Christensen KA, Stephens MA, Townsend AL. Mastery in women's multiple roles and well-being: adult daughters providing care to impaired parents. *Health Psychol*. 1998;17(2):163-71.
61. Schubart JR, Kinzie MB, Farace E. Caring for the brain tumor patient: family caregiver burden and unmet needs. *Neuro-oncology*. 2008;10(1):61-72.
62. Boele FW, Grant R, Sherwood P. Challenges and support for family caregivers of glioma patients. *British Journal of Neuroscience Nursing*. 2017;13(1):8-16.
63. Langbecker D, Janda M. Systematic review of interventions to improve the provision of information for adults with primary brain tumors and their caregivers. *Front Oncol*. 2015;5:1.
64. Hricik A, Donovan H, Bradley SE, Given BA, Bender CM, Newberry A, et al. Changes in caregiver perceptions over time in response to providing care for a loved one with a primary malignant brain tumor. *Oncol Nurs Forum*. 2011;38(2):149-55.
65. Boele FW, Hoeben W, Hilverda K, Lenting J, Calis AL, Sizoo EM, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma patients: a randomized controlled trial. *Journal of neuro-oncology*. 2013;111(3):303-11.

Appendices

# CURRICULUM VITAE

Marthe Peeters was born on April 21nd, 1994 in Leiden and raised in Voorschoten. After graduating from the Stedelijk Gymnasium in Leiden, she studied Medicine at Leiden University.

After obtaining her Bachelor's degree in Medicine, she started a research internship at the department of Neurology in the Leiden University Medical Center in September 2015 under supervision of prof.dr. Martin J.B. Taphoorn and dr. Linda Dirven. The aim of this research project concerned prediagnostic symptoms in glioma patients.

During her clinical internships, from May 2016- April 2018 (coschappen), she continued her research at the department of Neuro-oncology. From 2018 to 2020, she worked full-time as PhD student and the results of her research internship and her PhD project are described in this thesis.

In August 2020, she continued her study Medicine and obtained her Master's degree on February 26th, 2021. Since then, she worked as a physician not in training (ANIOS) at the departments of Urology at Alrijne Hospital in Leiderdorp and LUMC.

Marthe lives with her partner Peter van Dam in Voorhout.

Appendices

## LIST OF PUBLICATIONS

Fritz L, Peeters MCM, Zwinkels H, Koekkoek JAF, Reijneveld JC, Vos MJ, et al. Advance care planning (ACP) in glioblastoma patients: Evaluation of a disease-specific ACP program and impact on outcomes. *Neurooncol Pract.* 2022;npac050.

Peeters MCM, Ottenheijm GSGJ, Bienfait HP, Eekers DBP, Gijtenbeek JJM, Hanse MCJ, et al. Glioma patient-reported outcomes: patients and clinicians. *BMJ Support Palliat Care.* 2021;bmjspcare-2020-002699.

Coomans MB, Peeters MCM, Koekkoek JAF, Schoones JW, Reijneveld J, Taphoorn MJB, et al. Research Objectives, Statistical Analyses and Interpretation of Health-Related Quality of Life Data in Glioma Research: A Systematic Review. *Cancers (Basel).* 2020;12(12).

Peeters MCM, Zwinkels H, Koekkoek JAF, Vos MJ, Dirven L, Taphoorn MJB. The Impact of the Timing of Health-Related Quality of Life Assessments on the Actual Results in Glioma Patients: A Randomized Prospective Study. *Cancers (Basel).* 2020;12(8):2172.

Peeters MCM, Dirven L, Koekkoek JAF, Gortmaker EG, Fritz L, Vos MJ, et al. Prediagnostic symptoms and signs of adult glioma: the patients' view. *J Neurooncol.* 2020;146(2):293-301.

Peeters MCM, Dirven L, Koekkoek JAF, Numans ME, Taphoorn MJB. Prediagnostic presentations of glioma in primary care: a case-control study. *CNS Oncol.* 2019;8(3):CNS44.

Zamanipoor Najafabadi AH, Peeters MCM, Dirven L, Lobatto DJ, Groen JL, Broekman MLD, Peerdeman SM, Peul WC, Taphoorn MJB, van Furth WR. Impaired health-related quality of life in meningioma patients-a systematic review. *Neuro Oncol.* 2017;19(7):897-907.

Zamanipoor Najafabadi AH, Peeters MCM, Lobatto DJ, Broekman MLD, Smith TR, Biermasz NR, Peerdeman SM, Peul WC, Taphoorn MJB, van Furth WR, Dirven L. Health-related quality of life of cranial WHO grade I meningioma patients: are current questionnaires relevant? *Acta Neurochir (Wien).* 2017;159(11):2149-2159.

Appendices

## DANKWOORD

Een proefschrift kan alleen tot stand komen door de medewerking en inzet van velen. Mijn dank gaat als eerste uit naar alle patiënten die hebben deelgenomen aan de verschillende studies beschreven in dit proefschrift. Ik waardeer hun bijdrage aan ons onderzoek zeer, in een periode waarin zij geconfronteerd werden met een hersentumor.

Graag bedank ik mijn promotores prof. dr. Martin J.B. Taphoorn en co-promotores dr. Linda Dirven en dr. Johan Koekkoek. Jullie bevlogenheid en betrokkenheid bij mensen met een hersentumor en het doen van wetenschappelijk onderzoek hebben mij steeds opnieuw geïnspireerd.

Beste Martin, ik ben je dankbaar voor de kans die je mij met dit onderzoeksproject hebt geboden, eerst als wetenschapsstage-student en later als promovendus. Je hebt me geholpen het overzicht te bewaren en motiveerde mij steeds opnieuw om de artikelen tot een goed einde te brengen.

Beste Linda, dank voor je grote betrokkenheid bij de totstandkoming van dit proefschrift, ook in voor jou moeilijke omstandigheden. Jouw zorgvuldige commentaar en andere bijdragen zijn onmisbaar geweest in het hele traject, dank voor je steun, de gesprekken en de gezelligheid tijdens lunches en congressen.

Beste Johan, je deskundige reacties op de stukken, je enthousiasme en klinische blik waren altijd zeer waardevol.

Daarnaast wil ik alle collega's die betrokken zijn geweest bij de beschreven studies bedanken, in het bijzonder Maaike Vos, Lara Fritz en Hanneke Zwinkels, jullie passie voor deze patiëntengroep is een grote inspiratiebron. Bedankt voor de prettige samenwerking rondom een aantal van de studies.

Mede neuro-oncologie PhD studenten Pim van der Meer, Marijke Coomans, Amir Zamanipoor Najafabadi, Quirien Oort, dank voor jullie gezelligheid tijdens congressen en meetings. Robin, Victor en Simone, het was goed om van jullie als kamergenoten af en toe even te horen dat het ook bij jullie meestal wel maar niet altijd even makkelijk ging.

Alle collega's bij de Urologie in het Alrijne en het LUMC, bedankt dat ik bij jullie de eerste stappen mocht zetten in het dokter zijn! Ik heb het ervaren als een heel leerzame tijd.

Veel dank aan mijn vrienden voor de steun, gezelligheid en welkome afleiding. In het bijzonder Annelotte en Loes, voor jullie steun en herkenbare verhalen rondom een promotietraject. Bedankt Ruben, Rens en Jesper voor jullie nuchtere kijk op dit hele traject en aanmoedigingen om door te gaan. Lieve Christy, de etentjes met jou en

## Appendices

Joséphine waren onmisbaar. Dank aan de mannen van mijn roeiploeg op Die Leythe, de trainingen en koffie achteraf waren een fijne afleiding. Ook de vriendinnen die ik heb leren kennen bij Sempre Crescendo wil ik bedanken voor de gezellige etentjes, waarbij we altijd goed kunnen bijkletsen.

Lieve Corrie en Fijns bedankt voor jullie luisterend oor en bemoediging en familie in Limburg voor de attendheid en belangstelling tijdens dit traject.

Lieve papa en mama, dank voor de liefde, steun, hulp en waardevolle adviezen. Jullie hebben me geholpen om te laten zien wat ik kan en waard ben. Lieve zus Joséphine, met jou sporten, kletsen over van alles en koken zorgde voor een goede afleiding tijdens mijn promotietraject.

Liefste Peter, dankjewel voor je steun, aanmoediging en hulp. Zonder jou had ik dit niet kunnen afronden.



